{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:33:38Z","timestamp":1790696018720,"version":"4.1.0"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"21","license":[{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030B_182827"],"award-info":[{"award-number":["310030B_182827"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["CRSII5_180323"],"award-info":[{"award-number":["CRSII5_180323"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["P300P3_155374"],"award-info":[{"award-number":["P300P3_155374"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004361","name":"Krebsliga Schweiz","doi-asserted-by":"publisher","award":["KFS-4091-02-2017"],"award-info":[{"award-number":["KFS-4091-02-2017"]}],"id":[{"id":"10.13039\/501100004361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00018-020-03538-3","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T05:02:37Z","timestamp":1588568557000},"page":"4315-4324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Vaccination against the Epstein\u2013Barr virus"],"prefix":"10.1007","volume":"77","author":[{"given":"Julia","family":"R\u00fchl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol S.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6419-1940","authenticated-orcid":false,"given":"Christian","family":"M\u00fcnz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,4]]},"reference":[{"key":"3538_CR1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","volume":"17","author":"C M\u00fcnz","year":"2019","unstructured":"M\u00fcnz C (2019) Latency and lytic replication in the oncogenesis of the Epstein Barr virus. Nat Rev Micobiol 17:691\u2013700","journal-title":"Nat Rev Micobiol"},{"key":"3538_CR2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","volume":"1","author":"MA Epstein","year":"1964","unstructured":"Epstein MA, Achong BG, Barr YM (1964) Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1:702\u2013703","journal-title":"Lancet"},{"key":"3538_CR3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1084\/jem.121.5.761","volume":"121","author":"MA Epstein","year":"1964","unstructured":"Epstein MA, Henle G, Achong BG, Barr YM (1964) Morphological and biological studies on a virus in cultured lymphoblasts from Burkitt's lymphoma. J Exp Med 121:761\u2013770","journal-title":"J Exp Med"},{"key":"3538_CR4","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3389\/fonc.2019.00713","volume":"9","author":"C Shannon-Lowe","year":"2019","unstructured":"Shannon-Lowe C, Rickinson A (2019) The global landscape of EBV-associated tumors. Front Oncol 9:713","journal-title":"Front Oncol"},{"key":"3538_CR5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev.pathol.1.110304.100209","volume":"1","author":"JL Kutok","year":"2006","unstructured":"Kutok JL, Wang F (2006) Spectrum of Epstein\u2013Barr virus-associated diseases. Annu Rev Pathol 1:375\u2013404","journal-title":"Annu Rev Pathol"},{"issue":"107","key":"3538_CR6","doi-asserted-by":"crossref","first-page":"107fs7","DOI":"10.1126\/scitranslmed.3002878","volume":"3","author":"JI Cohen","year":"2011","unstructured":"Cohen JI, Fauci AS, Varmus H, Nabel GJ (2011) Epstein\u2013Barr virus: an important vaccine target for cancer prevention. Sci Transl Med 3(107):107fs7","journal-title":"Sci Transl Med"},{"key":"3538_CR7","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","volume":"33","author":"GS Taylor","year":"2015","unstructured":"Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD (2015) The immunology of Epstein\u2013Barr virus-induced disease. Annu Rev Immunol 33:787\u2013821","journal-title":"Annu Rev Immunol"},{"key":"3538_CR8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","volume":"102","author":"SK Dunmire","year":"2018","unstructured":"Dunmire SK, Verghese PS, Balfour HH Jr (2018) Primary Epstein\u2013Barr virus infection. J Clin Virol 102:84\u201392","journal-title":"J Clin Virol"},{"key":"3538_CR9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","volume":"13","author":"H Al-Samkari","year":"2018","unstructured":"Al-Samkari H, Berliner N (2018) Hemophagocytic lymphohistiocytosis. Annu Rev Pathol 13:27\u201349","journal-title":"Annu Rev Pathol"},{"issue":"11","key":"3538_CR10","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nrneurol.2012.198","volume":"8","author":"A Ascherio","year":"2012","unstructured":"Ascherio A, Munger KL, Lunemann JD (2012) The initiation and prevention of multiple sclerosis. Nat Rev Neurol 8(11):602\u2013612","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"3538_CR11","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41591-019-0523-2","volume":"25","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, Al-Rohil RN, Mobley BC, Salem JE et al (2019) A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med 25(8):1243\u20131250","journal-title":"Nat Med"},{"key":"3538_CR12","doi-asserted-by":"crossref","first-page":"e1007748","DOI":"10.1371\/journal.ppat.1007748","volume":"15","author":"B Chatterjee","year":"2019","unstructured":"Chatterjee B, Deng Y, Holler A, Nunez N, Azzi T, Vanoaica LD et al (2019) CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein\u2013Barr virus infection in vivo. PLoS Pathog 15:e1007748","journal-title":"PLoS Pathog"},{"issue":"3","key":"3538_CR13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nm830","volume":"9","author":"SM Tugizov","year":"2003","unstructured":"Tugizov SM, Berline JW, Palefsky JM (2003) Epstein\u2013Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med 9(3):307\u2013314","journal-title":"Nat Med"},{"issue":"14","key":"3538_CR14","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.1128\/JVI.00443-13","volume":"87","author":"SM Tugizov","year":"2013","unstructured":"Tugizov SM, Herrera R, Palefsky JM (2013) Epstein\u2013Barr virus transcytosis through polarized oral epithelial cells. J Virol 87(14):8179\u20138194","journal-title":"J Virol"},{"key":"3538_CR15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.coviro.2018.08.012","volume":"32","author":"TC Frost","year":"2018","unstructured":"Frost TC, Gewurz BE (2018) Epigenetic crossroads of the Epstein\u2013Barr virus B-cell relationship. Curr Opin Virol 32:15\u201323","journal-title":"Curr Opin Virol"},{"issue":"Pt 1","key":"3538_CR16","first-page":"151","volume":"390","author":"DA Thorley-Lawson","year":"2015","unstructured":"Thorley-Lawson DA (2015) EBV persistence\u2014introducing the virus. Curr Top Microbiol Immunol 390(Pt 1):151\u2013209","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"3538_CR17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1073\/pnas.2237267100","volume":"101","author":"D Hochberg","year":"2004","unstructured":"Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA (2004) Demonstration of the Burkitt's lymphoma Epstein\u2013Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci USA 101(1):239\u2013244","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"3538_CR18","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1128\/JVI.79.2.1296-1307.2005","volume":"79","author":"LL Laichalk","year":"2005","unstructured":"Laichalk LL, Thorley-Lawson DA (2005) Terminal differentiation into plasma cells initiates the replicative cycle of Epstein\u2013Barr virus in vivo. J Virol 79(2):1296\u20131307","journal-title":"J Virol"},{"key":"3538_CR19","first-page":"1","volume":"91","author":"LM Hutt-Fletcher","year":"2017","unstructured":"Hutt-Fletcher LM (2017) The long and complicated relationship between Epstein\u2013Barr virus and epithelial cells. J Virol. 91:1","journal-title":"J Virol."},{"issue":"1","key":"3538_CR20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/imr.12791","volume":"291","author":"S Latour","year":"2019","unstructured":"Latour S, Fischer A (2019) Signaling pathways involved in the T-cell-mediated immunity against Epstein\u2013Barr virus: lessons from genetic diseases. Immunol Rev 291(1):174\u2013189","journal-title":"Immunol Rev"},{"key":"3538_CR21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/femsre\/fuy044","volume":"43","author":"B Damania","year":"2019","unstructured":"Damania B, M\u00fcnz C (2019) Immunodeficiencies that predispose to pathologies by human oncogenic gamma-herpesviruses. FEMS Microbiol Rev 43:181\u2013192","journal-title":"FEMS Microbiol Rev"},{"issue":"4","key":"3538_CR22","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1182\/blood-2003-06-2171","volume":"103","author":"H Katano","year":"2004","unstructured":"Katano H, Ali MA, Patera AC, Catalfamo M, Jaffe ES, Kimura H et al (2004) Chronic active Epstein\u2013Barr virus infection associated with mutations in perforin that impair its maturation. Blood 103(4):1244\u20131252","journal-title":"Blood"},{"issue":"12","key":"3538_CR23","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.3324\/haematol.2010.029389","volume":"95","author":"J Rohr","year":"2010","unstructured":"Rohr J, Beutel K, Maul-Pavicic A, Vraetz T, Thiel J, Warnatz K et al (2010) Atypical familial hemophagocytic lymphohistiocytosis due to mutations in UNC13D and STXBP2 overlaps with primary immunodeficiency diseases. Haematologica 95(12):2080\u20132087","journal-title":"Haematologica"},{"issue":"5","key":"3538_CR24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10875-015-0168-y","volume":"35","author":"JI Cohen","year":"2015","unstructured":"Cohen JI, Niemela JE, Stoddard JL, Pittaluga S, Heslop H, Jaffe ES et al (2015) Late-onset severe chronic active EBV in a patient for five years with mutations in STXBP2 (MUNC18-2) and PRF1 (perforin 1). J Clin Immunol 35(5):445\u2013448","journal-title":"J Clin Immunol"},{"key":"3538_CR25","doi-asserted-by":"crossref","unstructured":"Salzer E, Daschkey S, Choo S, Gombert M, Santos-Valente E, Ginzel S, et al (2012) Combined immunodeficiency with life-threatening EBV-associatedlymphoproliferative disorder in patients lacking functional CD27. Haematologica","DOI":"10.3324\/haematol.2012.068791"},{"key":"3538_CR26","unstructured":"Schwab C, Gabrysch A, Olbrich P, Patino V, Warnatz K, Wolff D, et al (2018) Phenotype, penetrance, and treatment of 133 CTLA-4-insufficient individuals. J Allergy Clin Immunol"},{"issue":"3","key":"3538_CR27","doi-asserted-by":"crossref","first-page":"787e6","DOI":"10.1016\/j.jaci.2011.11.013","volume":"129","author":"JM van Montfrans","year":"2012","unstructured":"van Montfrans JM, Hoepelman AI, Otto S, van Gijn M, van de Corput L, de Weger RA et al (2012) CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. J Allergy Clin Immunol 129(3):787e6\u2013793e6","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"3538_CR28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/2424","volume":"20","author":"AJ Coffey","year":"1998","unstructured":"Coffey AJ, Brooksbank RA, Brandau O, Oohashi T, Howell GR, Bye JM et al (1998) Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 20(2):129\u2013135","journal-title":"Nat Genet"},{"issue":"23","key":"3538_CR29","doi-asserted-by":"crossref","first-page":"13765","DOI":"10.1073\/pnas.95.23.13765","volume":"95","author":"KE Nichols","year":"1998","unstructured":"Nichols KE, Harkin DP, Levitz S, Krainer M, Kolquist KA, Genovese C et al (1998) Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A 95(23):13765\u201313770","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6701","key":"3538_CR30","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/26683","volume":"395","author":"J Sayos","year":"1998","unstructured":"Sayos J, Wu C, Morra M, Wang N, Zhang X, Allen D et al (1998) The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 395(6701):462\u2013469","journal-title":"Nature"},{"issue":"2","key":"3538_CR31","first-page":"574 e5","volume":"144","author":"MF Alosaimi","year":"2019","unstructured":"Alosaimi MF, Hoenig M, Jaber F, Platt CD, Jones J, Wallace J et al (2019) Immunodeficiency and EBV-induced lymphoproliferation caused by 4\u20131BB deficiency. J Allergy Clin Immunol 144(2):574 e5\u2013583 e5","journal-title":"J Allergy Clin Immunol"},{"key":"3538_CR32","doi-asserted-by":"crossref","unstructured":"Somekh I, Thian M, Medgyesi D, Gulez N, Magg T, Gallon Duque A, et al (2019) CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis. Blood","DOI":"10.1182\/blood.2019000644"},{"issue":"6142","key":"3538_CR33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1126\/science.1240094","volume":"341","author":"B Chaigne-Delalande","year":"2013","unstructured":"Chaigne-Delalande B, Li FY, O'Connor GM, Lukacs MJ, Jiang P, Zheng L et al (2013) Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science 341(6142):186\u2013191","journal-title":"Science"},{"issue":"8","key":"3538_CR34","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/blood.V88.8.3022.bloodjournal8883022","volume":"88","author":"E de Vries","year":"1996","unstructured":"de Vries E, Koene HR, Vossen JM, Gratama JW, von dem Borne AE, Waaijer JL et al (1996) Identification of an unusual Fc gamma receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections. Blood 88(8):3022\u20133027","journal-title":"Blood"},{"issue":"5","key":"3538_CR35","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1172\/JCI37901","volume":"119","author":"K Huck","year":"2009","unstructured":"Huck K, Feyen O, Niehues T, Ruschendorf F, Hubner N, Laws HJ et al (2009) Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest 119(5):1350\u20131358","journal-title":"J Clin Invest"},{"issue":"7504","key":"3538_CR36","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nature13386","volume":"510","author":"E Martin","year":"2014","unstructured":"Martin E, Palmic N, Sanquer S, Lenoir C, Hauck F, Mongellaz C et al (2014) CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. Nature 510(7504):288\u2013292","journal-title":"Nature"},{"issue":"7115","key":"3538_CR37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature05257","volume":"444","author":"S Rigaud","year":"2006","unstructured":"Rigaud S, Fondaneche MC, Lambert N, Pasquier B, Mateo V, Soulas P et al (2006) XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444(7115):110\u2013114","journal-title":"Nature"},{"issue":"26","key":"3538_CR38","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJM198906293202605","volume":"320","author":"CA Biron","year":"1989","unstructured":"Biron CA, Byron KS, Sullivan JL (1989) Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 320(26):1731\u20131735","journal-title":"N Engl J Med"},{"issue":"4","key":"3538_CR39","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1086\/503269","volume":"78","author":"C Eidenschenk","year":"2006","unstructured":"Eidenschenk C, Dunne J, Jouanguy E, Fourlinnie C, Gineau L, Bacq D et al (2006) A novel primary immunodeficiency with specific natural-killer cell deficiency maps to the centromeric region of chromosome 8. Am J Hum Genet 78(4):721\u2013727","journal-title":"Am J Hum Genet"},{"issue":"7","key":"3538_CR40","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nri3466","volume":"13","author":"A Durandy","year":"2013","unstructured":"Durandy A, Kracker S, Fischer A (2013) Primary antibody deficiencies. Nat Rev Immunol 13(7):519\u2013533","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"3538_CR41","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S2213-2600(15)00202-7","volume":"3","author":"N Verma","year":"2015","unstructured":"Verma N, Grimbacher B, Hurst JR (2015) Lung disease in primary antibody deficiency. Lancet Respir Med 3(8):651\u2013660","journal-title":"Lancet Respir Med"},{"issue":"3","key":"3538_CR42","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jaip.2018.07.046","volume":"7","author":"RE El Hawary","year":"2019","unstructured":"El Hawary RE, Mauracher AA, Meshaal SS, Eldash A, Abd Elaziz DS, Alkady R et al (2019) MHC-II deficiency among egyptians: novel mutations and unique phenotypes. J Allergy Clin Immunol Pract 7(3):856\u2013863","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"19","key":"3538_CR43","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1182\/blood-2011-05-352716","volume":"118","author":"M Ouederni","year":"2011","unstructured":"Ouederni M, Vincent QB, Frange P, Touzot F, Scerra S, Bejaoui M et al (2011) Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients. Blood 118(19):5108\u20135118","journal-title":"Blood"},{"issue":"6","key":"3538_CR44","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1084\/jem.20081720","volume":"206","author":"T Strowig","year":"2009","unstructured":"Strowig T, Gurer C, Ploss A, Liu YF, Arrey F, Sashihara J et al (2009) Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med 206(6):1423\u20131434","journal-title":"J Exp Med"},{"issue":"6","key":"3538_CR45","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.celrep.2013.11.041","volume":"5","author":"O Chijioke","year":"2013","unstructured":"Chijioke O, Muller A, Feederle R, Barros MH, Krieg C, Emmel V et al (2013) Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein\u2013Barr virus infection. Cell Rep 5(6):1489\u20131498","journal-title":"Cell Rep"},{"issue":"20","key":"3538_CR46","doi-asserted-by":"crossref","first-page":"7935","DOI":"10.1158\/0008-5472.CAN-09-0828","volume":"69","author":"H Yuling","year":"2009","unstructured":"Yuling H, Ruijing X, Li L, Xiang J, Rui Z, Yujuan W et al (2009) EBV-induced human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies. Cancer Res 69(20):7935\u20137944","journal-title":"Cancer Res"},{"issue":"4","key":"3538_CR47","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ccr.2014.07.026","volume":"26","author":"Z Xiang","year":"2014","unstructured":"Xiang Z, Liu Y, Zheng J, Liu M, Lv A, Gao Y et al (2014) Targeted activation of human Vgamma9Vdelta2-T cells controls Epstein\u2013Barr virus-induced B cell lymphoproliferative disease. Cancer Cell 26(4):565\u2013576","journal-title":"Cancer Cell"},{"key":"3538_CR48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1172\/jci.insight.93179","volume":"2","author":"NA Zumwalde","year":"2017","unstructured":"Zumwalde NA, Sharma A, Xu X, Ma S, Schneider CL, Romero-Masters JC et al (2017) Adoptively transferred Vgamma9Vdelta2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model. JCI Insight 2:13","journal-title":"JCI Insight"},{"issue":"1773","key":"3538_CR49","doi-asserted-by":"crossref","first-page":"20180296","DOI":"10.1098\/rstb.2018.0296","volume":"374","author":"D McHugh","year":"2019","unstructured":"McHugh D, Caduff N, Murer A, Engelmann C, Deng Y, Zdimerova H et al (2019) Infection and immune control of human oncogenic gamma-herpesviruses in humanized mice. Philos Trans R Soc Lond B Biol Sci 374(1773):20180296","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"7620","key":"3538_CR50","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nature19317","volume":"537","author":"R He","year":"2016","unstructured":"He R, Hou S, Liu C, Zhang A, Bai Q, Han M et al (2016) Follicular CXCR5- expressing CD8+ T cells curtail chronic viral infection. Nature 537(7620):412\u2013428","journal-title":"Nature"},{"issue":"10","key":"3538_CR51","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ni.3543","volume":"17","author":"YA Leong","year":"2016","unstructured":"Leong YA, Chen Y, Ong HS, Wu D, Man K, Deleage C et al (2016) CXCR5+ follicular cytotoxic T cells control viral infection in B cell follicles. Nat Immunol 17(10):1187\u20131196","journal-title":"Nat Immunol"},{"key":"3538_CR52","first-page":"427","volume":"391","author":"S Gottschalk","year":"2015","unstructured":"Gottschalk S, Rooney CM (2015) Adoptive T-cell immunotherapy. Curr Top Microbiol Immunol 391:427\u2013454","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"3538_CR53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","volume":"31","author":"V Icheva","year":"2013","unstructured":"Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, Bethge W et al (2013) Adoptive transfer of Epstein\u2013Barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 31(1):39\u201348","journal-title":"J Clin Oncol"},{"issue":"11","key":"3538_CR54","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","volume":"36","author":"CM Bollard","year":"2018","unstructured":"Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V et al (2018) Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma. J Clin Oncol 36(11):1128\u20131139","journal-title":"J Clin Oncol"},{"issue":"5","key":"3538_CR55","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/0008-5472.CAN-11-3399","volume":"72","author":"C Smith","year":"2012","unstructured":"Smith C, Tsang J, Beagley L, Chua D, Lee V, Li V et al (2012) Effective treatment of metastatic forms of Epstein\u2013Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res 72(5):1116\u20131125","journal-title":"Cancer Res"},{"issue":"11","key":"3538_CR56","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1177\/1352458514521888","volume":"20","author":"MP Pender","year":"2014","unstructured":"Pender MP, Csurhes PA, Smith C, Beagley L, Hooper KD, Raj M et al (2014) Epstein\u2013Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. Mult Scler 20(11):1541\u20131544","journal-title":"Mult Scler"},{"key":"3538_CR57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1172\/jci.insight.124714","volume":"3","author":"MP Pender","year":"2018","unstructured":"Pender MP, Csurhes PA, Smith C, Douglas NL, Neller MA, Matthews KK et al (2018) Epstein\u2013Barr virus-specific T cell therapy for progressive multiple sclerosis. JCI Insight 3:22","journal-title":"JCI Insight"},{"issue":"2","key":"3538_CR58","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1128\/JVI.01777-06","volume":"81","author":"IY Pappworth","year":"2007","unstructured":"Pappworth IY, Wang EC, Rowe M (2007) The switch from latent to productive infection in Epstein\u2013Barr virus-infected B cells is associated with sensitization to NK cell killing. J Virol 81(2):474\u2013482","journal-title":"J Virol"},{"issue":"16","key":"3538_CR59","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood-2014-01-553024","volume":"124","author":"T Azzi","year":"2014","unstructured":"Azzi T, Lunemann A, Murer A, Ueda S, Beziat V, Malmberg KJ et al (2014) Role for early-differentiated natural killer cells in infectious mononucleosis. Blood 124(16):2533\u20132543","journal-title":"Blood"},{"issue":"12","key":"3538_CR60","doi-asserted-by":"crossref","first-page":"e1005286","DOI":"10.1371\/journal.ppat.1005286","volume":"11","author":"SK Dunmire","year":"2015","unstructured":"Dunmire SK, Grimm JM, Schmeling DO, Balfour HH Jr, Hogquist KA (2015) The incubation period of primary Epstein\u2013Barr virus infection: viral dynamics and immunologic events. PLoS Pathog 11(12):e1005286","journal-title":"PLoS Pathog"},{"issue":"2","key":"3538_CR61","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2141.2005.05452.x","volume":"129","author":"H Williams","year":"2005","unstructured":"Williams H, McAulay K, Macsween KF, Gallacher NJ, Higgins CD, Harrison N et al (2005) The immune response to primary EBV infection: a role for natural killer cells. Br J Haematol 129(2):266\u2013274","journal-title":"Br J Haematol"},{"issue":"10","key":"3538_CR62","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.4049\/jimmunol.1303211","volume":"192","author":"DW Hendricks","year":"2014","unstructured":"Hendricks DW, Balfour HH Jr, Dunmire SK, Schmeling DO, Hogquist KA, Lanier LL (2014) Cutting edge: NKG2ChiCD57+ NK cells respond specifically to acute infection with cytomegalovirus and not Epstein\u2013Barr virus. J Immunol 192(10):4492\u20134496","journal-title":"J Immunol"},{"issue":"6","key":"3538_CR63","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1084\/jem.20161017","volume":"214","author":"Z Djaoud","year":"2017","unstructured":"Djaoud Z, Guethlein LA, Horowitz A, Azzi T, Nemat-Gorgani N, Olive D et al (2017) Two alternate strategies for innate immunity to Epstein\u2013Barr virus: one using NK cells and the other NK cells and gammadelta T cells. J Exp Med 214(6):1827\u20131841","journal-title":"J Exp Med"},{"issue":"15","key":"3538_CR64","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/blood-2013-01-480665","volume":"122","author":"BK Chung","year":"2013","unstructured":"Chung BK, Tsai K, Allan LL, Zheng DJ, Nie JC, Biggs CM et al (2013) Innate immune control of EBV-infected B cells by invariant natural killer T cells. Blood 122(15):2600\u20132608","journal-title":"Blood"},{"key":"3538_CR65","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","volume":"41","author":"KJ Ewer","year":"2016","unstructured":"Ewer KJ, Lambe T, Rollier CS, Spencer AJ, Hill AV, Dorrell L (2016) Viral vectors as vaccine platforms: from immunogenicity to impact. Curr Opin Immunol 41:47\u201354","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"3538_CR66","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.coviro.2011.07.009","volume":"1","author":"JC Small","year":"2011","unstructured":"Small JC, Ertl HC (2011) Viruses\u2014from pathogens to vaccine carriers. Curr Opin Virol 1(4):241\u2013245","journal-title":"Curr Opin Virol"},{"issue":"3","key":"3538_CR67","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","volume":"2","author":"T Ura","year":"2014","unstructured":"Ura T, Okuda K, Shimada M (2014) Developments in viral vector-based vaccines. Vaccines (Basel) 2(3):624\u2013641","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"3538_CR68","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/biot.201400390","volume":"10","author":"H Kallel","year":"2015","unstructured":"Kallel H, Kamen AA (2015) Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials. Biotechnol J 10(5):741\u2013747","journal-title":"Biotechnol J"},{"key":"3538_CR69","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1128\/JVI.01729-16","volume":"91","author":"F Nasar","year":"2017","unstructured":"Nasar F, Matassov D, Seymour RL, Latham T, Gorchakov RV, Nowak RM et al (2017) Recombinant Isfahan virus and vesicular stomatitis virus vaccine vectors provide durable, multivalent, single-dose protection against lethal alphavirus challenge. J Virol 91:8","journal-title":"J Virol"},{"key":"3538_CR70","first-page":"171","volume":"84","author":"SY Gu","year":"1995","unstructured":"Gu SY, Huang TM, Ruan L, Miao YH, Lu H, Chu CM et al (1995) First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 84:171\u2013177","journal-title":"Dev Biol Stand"},{"issue":"21","key":"3538_CR71","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1001\/jama.294.21.2734","volume":"294","author":"CG Casey","year":"2005","unstructured":"Casey CG, Iskander JK, Roper MH, Mast EE, Wen XJ, Torok TJ et al (2005) Adverse events associated with smallpox vaccination in the United States, January\u2013October 2003. JAMA 294(21):2734\u20132743","journal-title":"JAMA"},{"issue":"4","key":"3538_CR72","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3390\/v7041726","volume":"7","author":"L Sanchez-Sampedro","year":"2015","unstructured":"Sanchez-Sampedro L, Perdiguero B, Mejias-Perez E, Garcia-Arriaza J, Di Pilato M, Esteban M (2015) The evolution of poxvirus vaccines. Viruses 7(4):1726\u20131803","journal-title":"Viruses"},{"issue":"8","key":"3538_CR73","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2006.10.047","volume":"25","author":"J Parrino","year":"2007","unstructured":"Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME et al (2007) Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 25(8):1513\u20131525","journal-title":"Vaccine"},{"issue":"19","key":"3538_CR74","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","volume":"20","author":"GS Taylor","year":"2014","unstructured":"Taylor GS, Jia H, Harrington K, Lee LW, Turner J, Ladell K et al (2014) A recombinant modified vaccinia ankara vaccine encoding Epstein\u2013Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res 20(19):5009\u20135022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3538_CR75","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","volume":"73","author":"EP Hui","year":"2013","unstructured":"Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R et al (2013) Phase I trial of recombinant modified vaccinia ankara encoding Epstein\u2013Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res 73(6):1676\u20131688","journal-title":"Cancer Res"},{"issue":"4","key":"3538_CR76","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/annonc\/mdr341","volume":"23","author":"WK Chia","year":"2012","unstructured":"Chia WK, Wang WW, Teo M, Tai WM, Lim WT, Tan EH et al (2012) A phase II study evaluating the safety and efficacy of an adenovirus-DeltaLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol 23(4):997\u20131005","journal-title":"Ann Oncol"},{"issue":"8","key":"3538_CR77","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","volume":"32","author":"CM Bollard","year":"2014","unstructured":"Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y et al (2014) Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein\u2013Barr virus latent membrane proteins. J Clin Oncol 32(8):798\u2013808","journal-title":"J Clin Oncol"},{"issue":"7","key":"3538_CR78","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.4049\/jimmunol.177.7.4897","volume":"177","author":"C Smith","year":"2006","unstructured":"Smith C, Cooper L, Burgess M, Rist M, Webb N, Lambley E et al (2006) Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope. J Immunol 177(7):4897\u20134906","journal-title":"J Immunol"},{"issue":"4","key":"3538_CR79","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1586\/erv.13.15","volume":"12","author":"S Capone","year":"2013","unstructured":"Capone S, D'Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A et al (2013) Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines 12(4):379\u2013393","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"3538_CR80","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","volume":"7","author":"MD Dicks","year":"2012","unstructured":"Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC et al (2012) A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS ONE 7(7):e40385","journal-title":"PLoS ONE"},{"issue":"3","key":"3538_CR81","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","volume":"21","author":"S Lu","year":"2009","unstructured":"Lu S (2009) Heterologous prime-boost vaccination. Curr Opin Immunol 21(3):346\u2013351","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"3538_CR82","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","volume":"34","author":"K Kardani","year":"2016","unstructured":"Kardani K, Bolhassani A, Shahbazi S (2016) Prime-boost vaccine strategy against viral infections: mechanisms and benefits. Vaccine 34(4):413\u2013423","journal-title":"Vaccine"},{"issue":"9","key":"3538_CR83","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1586\/erv.10.106","volume":"9","author":"RM Paris","year":"2010","unstructured":"Paris RM, Kim JH, Robb ML, Michael NL (2010) Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vaccines 9(9):1055\u20131069","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"3538_CR84","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1586\/14760584.2016.1158108","volume":"15","author":"T Musich","year":"2016","unstructured":"Musich T, Robert-Guroff M (2016) New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design. Expert Rev Vaccines 15(8):1015\u20131027","journal-title":"Expert Rev Vaccines"},{"key":"3538_CR85","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","volume":"4","author":"KJ Ewer","year":"2013","unstructured":"Ewer KJ, O'Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A et al (2013) Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 4:2836","journal-title":"Nat Commun"},{"issue":"261","key":"3538_CR86","doi-asserted-by":"crossref","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","volume":"6","author":"L Swadling","year":"2014","unstructured":"Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW et al (2014) A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 6(261):261ra153","journal-title":"Sci Transl Med"},{"issue":"8","key":"3538_CR87","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/infdis\/jiy639","volume":"219","author":"N Venkatraman","year":"2019","unstructured":"Venkatraman N, Ndiaye BP, Bowyer G, Wade D, Sridhar S, Wright D et al (2019) Safety and immunogenicity of a heterologous prime-boost ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal. J Infect Dis 219(8):1187\u20131197","journal-title":"J Infect Dis"},{"issue":"29","key":"3538_CR88","doi-asserted-by":"crossref","first-page":"47474","DOI":"10.18632\/oncotarget.17666","volume":"8","author":"F Cappuccini","year":"2017","unstructured":"Cappuccini F, Pollock E, Stribbling S, Hill AVS, Redchenko I (2017) 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy. Oncotarget 8(29):47474\u201347489","journal-title":"Oncotarget"},{"key":"3538_CR89","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1172\/JCI125364","volume":"129","author":"J Ruhl","year":"2019","unstructured":"Ruhl J, Citterio C, Engelmann C, Haigh TA, Dzionek A, Dreyer JH et al (2019) Heterologous prime-boost vaccination protects from EBV antigen expressing lymphomas. J Clin Invest 129:2071\u20132087","journal-title":"J Clin Invest"},{"key":"3538_CR90","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2008-03-148072","volume":"112","author":"C Gurer","year":"2008","unstructured":"Gurer C, Strowig T, Brilot F, Pack M, Trumpfheller C, Arrey F et al (2008) Targeting the nuclear antigen 1 of Epstein Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 112:1231\u20131239","journal-title":"Blood"},{"issue":"9","key":"3538_CR91","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood-2012-08-450775","volume":"121","author":"CS Leung","year":"2013","unstructured":"Leung CS, Maurer MA, Meixlsperger S, Lippmann A, Cheong C, Zuo J et al (2013) Robust T-cell stimulation by Epstein\u2013Barr virus-transformed B cells after antigen targeting to DEC-205. Blood 121(9):1584\u20131594","journal-title":"Blood"},{"issue":"25","key":"3538_CR92","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1182\/blood-2012-12-473413","volume":"121","author":"S Meixlsperger","year":"2013","unstructured":"Meixlsperger S, Leung CS, Ramer PC, Pack M, Vanoaica LD, Breton G et al (2013) CD141+ dendritic cells produce prominent amounts of IFN-alpha after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood 121(25):5034\u20135044","journal-title":"Blood"},{"issue":"17","key":"3538_CR93","doi-asserted-by":"crossref","first-page":"7131","DOI":"10.1073\/pnas.1103869108","volume":"108","author":"BJ Flynn","year":"2011","unstructured":"Flynn BJ, Kastenmuller K, Wille-Reece U, Tomaras GD, Alam M, Lindsay RW et al (2011) Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci USA 108(17):7131\u20137136","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9580","key":"3538_CR94","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","volume":"369","author":"J Paavonen","year":"2007","unstructured":"Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369(9580):2161\u20132170","journal-title":"Lancet"},{"issue":"39","key":"3538_CR95","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1016\/j.vaccine.2018.08.033","volume":"36","author":"JA Chichester","year":"2018","unstructured":"Chichester JA, Green BJ, Jones RM, Shoji Y, Miura K, Long CA et al (2018) Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: a Phase 1 dose-escalation study in healthy adults. Vaccine 36(39):5865\u20135871","journal-title":"Vaccine"},{"key":"3538_CR96","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12967-015-0415-2","volume":"13","author":"JG Ogembo","year":"2015","unstructured":"Ogembo JG, Muraswki MR, McGinnes LW, Parcharidou A, Sutiwisesak R, Tison T et al (2015) A chimeric EBV gp350\/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice. J Transl Med 13:50","journal-title":"J Transl Med"},{"issue":"12","key":"3538_CR97","doi-asserted-by":"crossref","first-page":"19255","DOI":"10.18632\/oncotarget.13770","volume":"8","author":"EM Perez","year":"2017","unstructured":"Perez EM, Foley J, Tison T, Silva R, Ogembo JG (2017) Novel Epstein\u2013Barr virus-like particles incorporating gH\/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice. Oncotarget 8(12):19255\u201319273","journal-title":"Oncotarget"},{"issue":"8","key":"3538_CR98","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1128\/JVI.02227-07","volume":"82","author":"D Adhikary","year":"2008","unstructured":"Adhikary D, Behrends U, Feederle R, Delecluse HJ, Mautner J (2008) Standardized and highly efficient expansion of Epstein\u2013Barr virus-specific CD4+ T cells by using virus-like particles. J Virol 82(8):3903\u20133911","journal-title":"J Virol"},{"issue":"5","key":"3538_CR99","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1128\/JVI.69.5.3147-3155.1995","volume":"69","author":"J Zimmermann","year":"1995","unstructured":"Zimmermann J, Hammerschmidt W (1995) Structure and role of the terminal repeats of Epstein\u2013Barr virus in processing and packaging of virion DNA. J Virol 69(5):3147\u20133155","journal-title":"J Virol"},{"issue":"9","key":"3538_CR100","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1073\/pnas.96.9.5188","volume":"96","author":"HJ Delecluse","year":"1999","unstructured":"Delecluse HJ, Pich D, Hilsendegen T, Baum C, Hammerschmidt W (1999) A first-generation packaging cell line for Epstein\u2013Barr virus-derived vectors. Proc Natl Acad Sci USA 96(9):5188\u20135193","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"3538_CR101","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.1128\/JVI.79.12.7641-7647.2005","volume":"79","author":"R Feederle","year":"2005","unstructured":"Feederle R, Shannon-Lowe C, Baldwin G, Delecluse HJ (2005) Defective infectious particles and rare packaged genomes produced by cells carrying terminal-repeat-negative Epstein\u2013Barr virus. J Virol 79(12):7641\u20137647","journal-title":"J Virol"},{"issue":"24","key":"3538_CR102","doi-asserted-by":"crossref","first-page":"13105","DOI":"10.1128\/JVI.05598-11","volume":"85","author":"R Ruiss","year":"2011","unstructured":"Ruiss R, Jochum S, Wanner G, Reisbach G, Hammerschmidt W, Zeidler R (2011) A virus-like particle-based Epstein\u2013Barr virus vaccine. J Virol 85(24):13105\u201313113","journal-title":"J Virol"},{"issue":"4","key":"3538_CR103","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1128\/JVI.02533-12","volume":"87","author":"S Pavlova","year":"2013","unstructured":"Pavlova S, Feederle R, Gartner K, Fuchs W, Granzow H, Delecluse HJ (2013) An Epstein\u2013Barr virus mutant produces immunogenic defective particles devoid of viral DNA. J Virol 87(4):2011\u20132022","journal-title":"J Virol"},{"issue":"12","key":"3538_CR104","doi-asserted-by":"crossref","first-page":"e1007464","DOI":"10.1371\/journal.ppat.1007464","volume":"14","author":"DG van Zyl","year":"2018","unstructured":"van Zyl DG, Tsai MH, Shumilov A, Schneidt V, Poirey R, Schlehe B et al (2018) Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice. PLoS Pathog 14(12):e1007464","journal-title":"PLoS Pathog"},{"issue":"2","key":"3538_CR105","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.celrep.2013.01.023","volume":"3","author":"JG Ogembo","year":"2013","unstructured":"Ogembo JG, Kannan L, Ghiran I, Nicholson-Weller A, Finberg RW, Tsokos GC et al (2013) Human complement receptor type 1\/CD35 is an Epstein\u2013Barr Virus receptor. Cell Rep 3(2):371\u2013385","journal-title":"Cell Rep"},{"issue":"6","key":"3538_CR106","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1128\/JVI.71.6.4657-4662.1997","volume":"71","author":"Q Li","year":"1997","unstructured":"Li Q, Spriggs MK, Kovats S, Turk SM, Comeau MR, Nepom B et al (1997) Epstein\u2013Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J Virol 71(6):4657\u20134662","journal-title":"J Virol"},{"key":"3538_CR107","first-page":"221","volume":"391","author":"LS Chesnokova","year":"2015","unstructured":"Chesnokova LS, Jiang R, Hutt-Fletcher LM (2015) Viral entry. Curr Top Microbiol Immunol 391:221\u2013235","journal-title":"Curr Top Microbiol Immunol"},{"key":"3538_CR108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2019.07.026","volume":"536","author":"LZ Mutsvunguma","year":"2019","unstructured":"Mutsvunguma LZ, Rodriguez E, Escalante GM, Muniraju M, Williams JC, Warden C et al (2019) Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein\u2013Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes. Virology 536:1\u201315","journal-title":"Virology"},{"key":"3538_CR109","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/cancers10040112","volume":"10","author":"JE Tanner","year":"2018","unstructured":"Tanner JE, Hu J, Alfieri C (2018) Construction and Characterization of a humanized anti-Epstein\u2013Barr virus gp350 antibody with neutralizing activity in cell culture. Cancers (Basel) 10:4","journal-title":"Cancers (Basel)"},{"issue":"12","key":"3538_CR110","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","volume":"196","author":"EM Sokal","year":"2007","unstructured":"Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Leonard P, Moreels A et al (2007) Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein\u2013Barr virus vaccine in healthy young adults. J Infect Dis 196(12):1749\u20131753","journal-title":"J Infect Dis"},{"issue":"24","key":"3538_CR111","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","volume":"25","author":"M Moutschen","year":"2007","unstructured":"Moutschen M, Leonard P, Sokal EM, Smets F, Haumont M, Mazzu P et al (2007) Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein\u2013Barr virus vaccine in healthy adults. Vaccine 25(24):4697\u20134705","journal-title":"Vaccine"},{"issue":"48","key":"3538_CR112","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1016\/j.vaccine.2015.10.024","volume":"33","author":"E Servat","year":"2015","unstructured":"Servat E, Ro BW, Cayatte C, Gemmell L, Barton C, Rao E et al (2015) Identification of the critical attribute(s) of EBV gp350 antigen required for elicitation of a neutralizing antibody response in vivo. Vaccine 33(48):6771\u20136777","journal-title":"Vaccine"},{"issue":"30","key":"3538_CR113","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1016\/j.vaccine.2013.04.071","volume":"31","author":"X Cui","year":"2013","unstructured":"Cui X, Cao Z, Sen G, Chattopadhyay G, Fuller DH, Fuller JT et al (2013) A novel tetrameric gp350 1\u2013470 as a potential Epstein\u2013Barr virus vaccine. Vaccine 31(30):3039\u20133045","journal-title":"Vaccine"},{"key":"3538_CR114","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3389\/fimmu.2018.00932","volume":"9","author":"B Zhao","year":"2018","unstructured":"Zhao B, Zhang X, Krummenacher C, Song S, Gao L, Zhang H et al (2018) Immunization with Fc-based recombinant Epstein\u2013Barr virus gp350 elicits potent neutralizing humoral immune response in a BALB\/c mice model. Front Immunol 9:932","journal-title":"Front Immunol"},{"issue":"23","key":"3538_CR115","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/j.vaccine.2016.04.012","volume":"34","author":"DS Heeke","year":"2016","unstructured":"Heeke DS, Lin R, Rao E, Woo JC, McCarthy MP, Marshall JD (2016) Identification of GLA\/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits. Vaccine 34(23):2562\u20132569","journal-title":"Vaccine"},{"issue":"5","key":"3538_CR116","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1073\/pnas.77.5.2979","volume":"77","author":"GJ Hoffman","year":"1980","unstructured":"Hoffman GJ, Lazarowitz SG, Hayward SD (1980) Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein\u2013Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci USA 77(5):2979\u20132983","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"3538_CR117","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1128\/JVI.03269-14","volume":"89","author":"JE Tanner","year":"2015","unstructured":"Tanner JE, Coincon M, Leblond V, Hu J, Fang JM, Sygusch J et al (2015) Peptides designed to spatially depict the Epstein\u2013Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule. J Virol 89(9):4932\u20134941","journal-title":"J Virol"},{"issue":"34","key":"3538_CR118","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1016\/j.vaccine.2016.06.021","volume":"34","author":"X Cui","year":"2016","unstructured":"Cui X, Cao Z, Chen Q, Arjunaraja S, Snow AL, Snapper CM (2016) Rabbits immunized with Epstein\u2013Barr virus gH\/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350. Vaccine 34(34):4050\u20134055","journal-title":"Vaccine"},{"issue":"4","key":"3538_CR119","doi-asserted-by":"crossref","first-page":"799 e9","DOI":"10.1016\/j.immuni.2018.03.026","volume":"48","author":"J Snijder","year":"2018","unstructured":"Snijder J, Ortego MS, Weidle C, Stuart AB, Gray MD, McElrath MJ et al (2018) An antibody targeting the fusion machinery neutralizes dual-tropic infection and defines a site of vulnerability on Epstein\u2013Barr virus. Immunity 48(4):799 e9\u2013811 e9","journal-title":"Immunity"},{"issue":"5","key":"3538_CR120","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","volume":"162","author":"M Kanekiyo","year":"2015","unstructured":"Kanekiyo M, Bu W, Joyce MG, Meng G, Whittle JR, Baxa U et al (2015) Rational design of an Epstein\u2013Barr virus vaccine targeting the receptor-binding site. Cell 162(5):1090\u20131100","journal-title":"Cell"},{"issue":"5","key":"3538_CR121","first-page":"130 5 e6","volume":"50","author":"W Bu","year":"2019","unstructured":"Bu W, Joyce MG, Nguyen H, Banh DV, Aguilar F, Tariq Z et al (2019) Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein\u2013Barr virus in B cells and epithelial cells. Immunity 50(5):130 5 e6\u20131316 e6","journal-title":"Immunity"},{"issue":"3","key":"3538_CR122","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1128\/JVI.77.3.1840-1847.2003","volume":"77","author":"D Sitki-Green","year":"2003","unstructured":"Sitki-Green D, Covington M, Raab-Traub N (2003) Compartmentalization and transmission of multiple Epstein\u2013Barr virus strains in asymptomatic carriers. J Virol 77(3):1840\u20131847","journal-title":"J Virol"},{"issue":"11","key":"3538_CR123","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1128\/JVI.77.11.6546-6550.2003","volume":"77","author":"DM Walling","year":"2003","unstructured":"Walling DM, Brown AL, Etienne W, Keitel WA, Ling PD (2003) Multiple Epstein\u2013Barr virus infections in healthy individuals. J Virol 77(11):6546\u20136550","journal-title":"J Virol"},{"issue":"14","key":"3538_CR124","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa023141","volume":"349","author":"H Hjalgrim","year":"2003","unstructured":"Hjalgrim H, Askling J, Rostgaard K, Hamilton-Dutoit S, Frisch M, Zhang JS et al (2003) Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 349(14):1324\u20131332","journal-title":"N Engl J Med"},{"issue":"3","key":"3538_CR125","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.20820","volume":"59","author":"EL Thacker","year":"2006","unstructured":"Thacker EL, Mirzaei F, Ascherio A (2006) Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 59(3):499\u2013503","journal-title":"Ann Neurol"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-020-03538-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-020-03538-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-020-03538-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T19:08:11Z","timestamp":1620068891000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-020-03538-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":125,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["3538"],"URL":"https:\/\/doi.org\/10.1007\/s00018-020-03538-3","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,4]]},"assertion":[{"value":"15 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}